Translation and Validation of the Persian Version of the Scleroderma Health Assessment Questionnaire (Shaq) Publisher Pubmed



Nayebirad S¹ ; Emamzade A² ; Sedaghat M³ ; Montazeri A⁴ ; Gharibdoost F² ; Yaseri M⁵ ; Tamartash Z² ; Salehi S² ; Kiani T² ; Soltani S² ; Mohammadzadegan A² ; Eshaghi A² ; Madanipour MR² ; Atef Yekta R^{6, 7} Show All Authors
Source: Internal and Emergency Medicine Published:2023

Abstract

The present study aimed to translate and validate the Scleroderma Health Assessment Questionnaire (SHAQ) for Persian-speaking patients (SHAQ-P), using a cross-sectional study. This cross-sectional study included SSc patients with 2013 ACR/EULAR criteria. The SHAQ was translated using a forward–backward method. HAQ-DI and SSc-HAQ scores were calculated from the patient-answered questionnaires. Rheumatology experts assessed the face and content validities of the SHAQ-P. Psychometric properties of the SHAQ-P were then assessed: Structural validity was analyzed using principal component factor analysis. Discriminant and convergent validities were measured on subgroups of the initial patient population. Test–retest reliability was measured on patients who filled the SHAQ-P again after 1 month. The Scale-CVI-average (S-CVI/Ave) score for content validity was 88.7%. Face validity was measured to be 68.17% using the QQ10 questionnaire. Factor analysis revealed a two-factor structure with 20 out of 26 questions loading on the first factor (N = 285). One-way ANOVA showed that patients with a higher number of involved organs had higher average HAQ-DI and SSc-HAQ-scores (N = 60, P = 0.019 and 0.023, respectively). HAQ-DI and SSc-HAQ-scores were significantly correlated with the physical component score of SF36 (N = 31, correlation coefficient = – 0.65 and – 0.72, respectively). Reliability testing after one month demonstrated that HAQ-DI and SSc-HAQ-scores were significantly correlated with their initial (N = 40, correlation coefficient = 0.86 and 0.84, respectively), proving that the Persian SHAQ was a valid and reliable questionnaire to evaluate scleroderma patients' quality of life. © 2023, The Author(s), under exclusive licence to Societa Italiana di Medicina Interna (SIMI).